Fractyl Health (GUTS) EBITDA (2023 - 2026)
Fractyl Health's (GUTS) quarterly EBITDA came in at -$20.8 million in Q1 2026, up 15.91% YoY from -$18.0 million in Q1 2025, and up 10.58% on a QoQ basis from -$23.3 million in Q4 2025.
Fractyl Health (GUTS) EBITDA (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of EBITDA data on file, last reported at -$20.8 million in Q1 2026.
- Quarterly EBITDA rose 15.91% year-over-year to -$20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92.9 million (up 4.0% YoY) and the FY2025 annual result came in at -$96.8 million, down 3.51% from the prior year.
- EBITDA rose to -$20.8 million in Q1 2026, from -$23.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$11.9 million in Q2 2023 to a low of -$26.1 million in Q2 2025.
- A 4-year average of -$20.2 million and a median of -$22.7 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA tumbled 94.21% — and 2026, when it gained 15.91%.
- Tracing GUTS's EBITDA over 4 years: stood at -$13.0 million in 2023, then plunged by 94.21% to -$25.2 million in 2024, then advanced by 7.64% to -$23.3 million in 2025, then grew by 10.58% to -$20.8 million in 2026.
- The last three EBITDA figures came in at -$20.8 million (Q1 2026), -$23.3 million (Q4 2025), and -$22.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Fractyl Health | 109.12 Mn | 109.12 Mn | - | -19.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.10 Mn |
| Mar 31, 2026 | -20.82 Mn |
| Dec 31, 2025 | -23.28 Mn |
| Sep 30, 2025 | -22.69 Mn |
| Jun 30, 2025 | -26.08 Mn |
| Mar 31, 2025 | -24.76 Mn |
| Dec 31, 2024 | -25.21 Mn |
| Sep 30, 2024 | -23.79 Mn |
| Jun 30, 2024 | -22.99 Mn |
| Mar 31, 2024 | -21.54 Mn |
| Dec 31, 2023 | -12.98 Mn |
| Sep 30, 2023 | -13.87 Mn |
| Jun 30, 2023 | -11.88 Mn |
| Mar 31, 2023 | -12.11 Mn |